{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Style Desk", "lead_paragraph": "ON Tuesday afternoon Kelly Kreth, a 34-year-old marketing director from Manhattan, was in a meeting at work when she was overcome with the jitters, the familiar rumblings of what she feared would become a full-fledged panic attack. Ms. Kreth said she had no doubt about the cause: holiday stress. ''I have a lot of issues with the holidays,'' she said. ''There's all this supposed holiday cheer, and I feel inadequate because I never get up to that level of cheer. It's Thanksgiving and Christmas and New Year's. You want to be left alone, but in the next month I'm going to be with so many people that I don't have the luxury of freaking out and locking myself in a room.''", "headline": {"main": "High For The Holidays"}, "abstract": "Article on increase in use of antidepressants and anti-anxiety drugs during winter holiday season, available either legally, through doctors' prescriptions, or from Internet drug sellers or friends; doctors comment on drugs that are most effective and caution about self-medicating or taking higher doses; drawings (M)", "print_page": "1", "word_count": 1441, "_id": "4fd23f218eb7c8105d7d6696", "snippet": "The age of psychopharmaceuticals has changed the preferred method of self-medication for holiday stress.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/11/28/fashion/28HIGH.html", "multimedia": [{"url": "images/2004/11/28/fashion/28high75.jpg", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2004/11/28/fashion/28high75.jpg"}, "type": "image", "height": 75}], "subsection_name": null, "keywords": [{"name": "persons", "value": "ST JOHN, WARREN"}, {"name": "subject", "value": "THANKSGIVING DAY"}, {"name": "subject", "value": "NEW YEAR"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "STRESS (HUMAN)"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "ANTIDEPRESSANTS"}, {"name": "subject", "value": "FAMILIES AND FAMILY LIFE"}, {"name": "subject", "value": "COMPUTERS AND THE INTERNET"}, {"name": "subject", "value": "CHRISTMAS"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Warren", "rank": 1, "lastname": "ST"}], "original": "By WARREN ST. JOHN and ALEX WILLIAMS"}, "document_type": "article", "pub_date": "2004-11-28T00:00:00Z", "section_name": "Technology; Health; Style"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "With his condition deteriorating from Parkinson's disease last year, Steve Kaufman gave up making improvements to his home in Algonquin, Ill. ''I couldn't even hold a nail stable,'' he recalled. Earlier this year, after taking an experimental drug in a clinical trial, Mr. Kaufman built new kitchen cabinets and an outdoor deck. He was so steady he could walk across a narrow piece of lumber like an Olympic gymnast on the balance beam.", "headline": {"main": "Many See Hope In Drug Pulled During Testing"}, "abstract": "Amgen, biotechnology company, earlier in year withdrew experimental drug for Parkinson's disease called glial cell line-derived neurotrophic factor (GDNF) because of safety issues; says drug had not proved better than placebo; Amgen's move has provoked outcry from some patients who say company is robbing them of their only hope; story of Amgen's drug shows clash between faith of patients and cold logic of science and business; photo of Steve Kaufman, Parkinson's patient who says he was making progress with GDNF (M)", "print_page": "1", "word_count": 2216, "_id": "4fd2a5638eb7c8105d88ca31", "snippet": "Some Parkinson's patients say drug developer Amgen robbed them of their only hope by ordering all patients off an experimental drug.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/11/26/business/26amgen.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "KAUFMAN, STEVE"}, {"name": "organizations", "value": "AMGEN INC"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "GDNF (DRUG)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "PARKINSON'S DISEASE"}, {"name": "subject", "value": "TESTS AND TESTING"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Andrew", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2004-11-26T00:00:00Z", "section_name": "Front Page; Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Taser International, whose electrical guns are used by thousands of police departments nationwide, says that a federal study endorses the safety of its guns, but the laboratory that conducted the research disagrees. Taser said last month that the government study, whose full results have not yet been released, found that its guns were safe. Since that statement, the company's stock has soared and its executives and directors have sold $68 million in shares, about 5 percent of Taser's stock and nearly half their holdings.", "headline": {"main": "Claims Over Tasers' Safety Are Challenged"}, "abstract": "Air Force laboratory that conducted research into safety of Taser International's stun guns disputes Taser's claim that study endorsed safety of its guns; Taser stock price soared after company's announcement; now laboratory says it found that guns could be dangerous and that more data is needed to evaluate their risks; Taser says it stands behind its original statement; more than 5,500 police departments and prisons now use Tasers; diagram; graph (M)", "print_page": "1", "word_count": 1028, "_id": "4fd249838eb7c8105d7e6f71", "snippet": "Taser International says that a study endorses the safety of its electrical guns, but the laboratory that conducted the research disagrees.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/11/26/business/26taser.html", "multimedia": [{"url": "images/2004/11/26/business/taser.75.jpg", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2004/11/26/business/taser.75.jpg"}, "type": "image", "height": 75}], "subsection_name": null, "keywords": [{"name": "organizations", "value": "TASER INTERNATIONAL"}, {"name": "subject", "value": "ACCIDENTS AND SAFETY"}, {"name": "subject", "value": "POLICE BRUTALITY AND MISCONDUCT"}, {"name": "subject", "value": "ARMAMENT, DEFENSE AND MILITARY FORCES"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "STUN GUNS"}, {"name": "subject", "value": "POLICE"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Alex", "rank": 1, "lastname": "BERENSON"}], "original": "By ALEX BERENSON"}, "document_type": "article", "pub_date": "2004-11-26T00:00:00Z", "section_name": "Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "For all the risks associated with Merck's arthritis and pain drug Vioxx, the company has always pointed to one virtue: Vioxx was less likely to cause ulcers or stomach bleeding than cheaper over-the-counter medications like Advil or Aleve. But as far back as 2001, Merck officials had evidence, based on the company's own research, that this might not be true for potentially hundreds of thousands of Vioxx users -- those, mostly middle-aged and older, who regularly took low doses of aspirin, not for pain, but to reduce their risk of heart attack or stroke.", "headline": {"main": "Questions Are Seen On Merck's Stance On Pain Drug's Use"}, "abstract": "Merck officials have had evidence since 2001 that its arthritis and pain drug Vioxx, pulled from market in Sept for increased heart risks, might fail to offer users who take low doses of aspirin drug's most touted benefit, less risk of ulcers or stomach bleeding than cheaper over-the-counter pain drugs; company noted finding in drug's 2003 label, but did not follow up on its plan to further study how significantly low-dose aspirin could reduce drug's gastrointestinal benefits; at issue is whether many patients and their insurers are spending heavily on costly class of drugs known as COX-2 inhibitors when they could get similar benefits from older, cheaper drugs; two other top sellers in class, Celebrex and Bextra, both made by Pfizer Inc, have not been proved to provide better protection for any class of patients (M)", "print_page": "1", "word_count": 1514, "_id": "4fd23f208eb7c8105d7d6608", "snippet": "Merck officials had evidence as far back as 2001 that Vioxx might not help thousands of users of the arthritis and pain drug.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/11/24/business/24vioxx.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "NOVARTIS"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "PFIZER INC"}, {"name": "organizations", "value": "MERCK & COMPANY INCORPORATED"}, {"name": "organizations", "value": "PFIZER INCORPORATED"}, {"name": "organizations", "value": "MERCK GROUP"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "CELEBREX (DRUG)"}, {"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "ULCERS"}, {"name": "subject", "value": "BEXTRA (DRUG)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "LABELING AND LABELS"}, {"name": "subject", "value": "COX-2 INHIBITORS (DRUGS)"}, {"name": "subject", "value": "STOMACH"}, {"name": "subject", "value": "PAIN-RELIEVING DRUGS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "ASPIRIN"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Barry", "rank": 1, "lastname": "MEIER"}], "original": "By BARRY MEIER"}, "document_type": "article", "pub_date": "2004-11-24T00:00:00Z", "section_name": "Front Page; Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "The United States needs a better system to detect harmful effects of drugs already on the market, and it should be independent of the Food and Drug Administration and the drug industry, medical researchers and journal editors said yesterday. Arguing that it was unreasonable to expect the same agency that approves drugs to ''also be committed to actively seek evidence to prove itself wrong,'' the editors of The Journal of the American Medical Association recommended that the nation consider establishing an ''independent drug safety board'' to track the safety of drugs and medical devices after they were approved and in widespread use.", "headline": {"main": "A Medical Journal Calls for a New Watchdog on Drugs"}, "abstract": "Medical researchers and editors of Journal of American Medical Assn contend United States needs a better system to detect harmful effects of drugs already on market, and it should be independent of FDA and drug industry; argue that it is unreasonable to expect same agency that approves drugs to 'also be committed to actively seek evidence to prove itself wrong'; recommend that nation consider establishing 'independent drug safety board' to trace safety of drugs and medical devices after they are approved and are in widespread use (M)", "print_page": "18", "word_count": 1252, "_id": "4fd23f208eb7c8105d7d65b9", "snippet": "Medical researchers said the U.S. needs a system independent of the F.D.A. to detect harmful effects of drugs already on the market.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/11/23/national/23fda.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "JOURNAL OF THE AMERICAN MEDICAL ASSN"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Denise", "rank": 1, "lastname": "GRADY"}], "original": "By DENISE GRADY"}, "document_type": "article", "pub_date": "2004-11-23T00:00:00Z", "section_name": "Health; U.S."}], "meta": {"hits": 5, "offset": 0, "time": 217}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}